Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice

Jiyoung Moon, Hyun Ju Do, Yoonsu Cho, Min-Jeong Shin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: We examined whether arginase inhibition influences hepatic metabolic pathways and whole body adiposity in diet-induced obesity. Methods and Results: After obesity induction by a high fat diet (HFD), mice were fed either the HFD or the HFD with an arginase inhibitor, Nω-hydroxy-nor- L-arginine (nor-NOHA). Nor-NOHA significantly prevented HFD-induced increases in body, liver, and visceral fat tissue weight, and ameliorated abnormal lipid profiles. Furthermore, nor-NOHA treatment reduced lipid accumulation in oleic acid-induced hepatic steatosis in vitro. Arginase inhibition increased hepatic nitric oxide (NO) in HFD-fed mice and HepG2 cells, and reversed the elevated mRNA expression of hepatic genes in lipid metabolism. Expression of phosphorylated 5′ AMPK-activated protein kinase α was increased by arginase inhibition in the mouse livers and HepG2 cells. Conclusions: Arginase inhibition ameliorated obesity-induced hepatic lipid abnormalities and whole body adiposity, possibly as a result of increased hepatic NO production and subsequent activation of metabolic pathways involved in hepatic triglyceride metabolism and mitochondrial function.

Original languageEnglish
Article numbere103048
JournalPLoS One
Volume9
Issue number7
DOIs
Publication statusPublished - 2014 Jul 24

Fingerprint

Arginase
arginase
Obese Mice
Nutrition
Fats
high fat diet
liver
High Fat Diet
Liver
mice
Lipids
obesity
Nitric Oxide
adiposity
Obesity
Adiposity
Hep G2 Cells
Metabolic Networks and Pathways
nitric oxide
biochemical pathways

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice. / Moon, Jiyoung; Do, Hyun Ju; Cho, Yoonsu; Shin, Min-Jeong.

In: PLoS One, Vol. 9, No. 7, e103048, 24.07.2014.

Research output: Contribution to journalArticle

Moon, Jiyoung ; Do, Hyun Ju ; Cho, Yoonsu ; Shin, Min-Jeong. / Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice. In: PLoS One. 2014 ; Vol. 9, No. 7.
@article{92cadde916834c2c8ae2d74ad152808c,
title = "Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice",
abstract = "Objectives: We examined whether arginase inhibition influences hepatic metabolic pathways and whole body adiposity in diet-induced obesity. Methods and Results: After obesity induction by a high fat diet (HFD), mice were fed either the HFD or the HFD with an arginase inhibitor, Nω-hydroxy-nor- L-arginine (nor-NOHA). Nor-NOHA significantly prevented HFD-induced increases in body, liver, and visceral fat tissue weight, and ameliorated abnormal lipid profiles. Furthermore, nor-NOHA treatment reduced lipid accumulation in oleic acid-induced hepatic steatosis in vitro. Arginase inhibition increased hepatic nitric oxide (NO) in HFD-fed mice and HepG2 cells, and reversed the elevated mRNA expression of hepatic genes in lipid metabolism. Expression of phosphorylated 5′ AMPK-activated protein kinase α was increased by arginase inhibition in the mouse livers and HepG2 cells. Conclusions: Arginase inhibition ameliorated obesity-induced hepatic lipid abnormalities and whole body adiposity, possibly as a result of increased hepatic NO production and subsequent activation of metabolic pathways involved in hepatic triglyceride metabolism and mitochondrial function.",
author = "Jiyoung Moon and Do, {Hyun Ju} and Yoonsu Cho and Min-Jeong Shin",
year = "2014",
month = "7",
day = "24",
doi = "10.1371/journal.pone.0103048",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice

AU - Moon, Jiyoung

AU - Do, Hyun Ju

AU - Cho, Yoonsu

AU - Shin, Min-Jeong

PY - 2014/7/24

Y1 - 2014/7/24

N2 - Objectives: We examined whether arginase inhibition influences hepatic metabolic pathways and whole body adiposity in diet-induced obesity. Methods and Results: After obesity induction by a high fat diet (HFD), mice were fed either the HFD or the HFD with an arginase inhibitor, Nω-hydroxy-nor- L-arginine (nor-NOHA). Nor-NOHA significantly prevented HFD-induced increases in body, liver, and visceral fat tissue weight, and ameliorated abnormal lipid profiles. Furthermore, nor-NOHA treatment reduced lipid accumulation in oleic acid-induced hepatic steatosis in vitro. Arginase inhibition increased hepatic nitric oxide (NO) in HFD-fed mice and HepG2 cells, and reversed the elevated mRNA expression of hepatic genes in lipid metabolism. Expression of phosphorylated 5′ AMPK-activated protein kinase α was increased by arginase inhibition in the mouse livers and HepG2 cells. Conclusions: Arginase inhibition ameliorated obesity-induced hepatic lipid abnormalities and whole body adiposity, possibly as a result of increased hepatic NO production and subsequent activation of metabolic pathways involved in hepatic triglyceride metabolism and mitochondrial function.

AB - Objectives: We examined whether arginase inhibition influences hepatic metabolic pathways and whole body adiposity in diet-induced obesity. Methods and Results: After obesity induction by a high fat diet (HFD), mice were fed either the HFD or the HFD with an arginase inhibitor, Nω-hydroxy-nor- L-arginine (nor-NOHA). Nor-NOHA significantly prevented HFD-induced increases in body, liver, and visceral fat tissue weight, and ameliorated abnormal lipid profiles. Furthermore, nor-NOHA treatment reduced lipid accumulation in oleic acid-induced hepatic steatosis in vitro. Arginase inhibition increased hepatic nitric oxide (NO) in HFD-fed mice and HepG2 cells, and reversed the elevated mRNA expression of hepatic genes in lipid metabolism. Expression of phosphorylated 5′ AMPK-activated protein kinase α was increased by arginase inhibition in the mouse livers and HepG2 cells. Conclusions: Arginase inhibition ameliorated obesity-induced hepatic lipid abnormalities and whole body adiposity, possibly as a result of increased hepatic NO production and subsequent activation of metabolic pathways involved in hepatic triglyceride metabolism and mitochondrial function.

UR - http://www.scopus.com/inward/record.url?scp=84904802745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904802745&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0103048

DO - 10.1371/journal.pone.0103048

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e103048

ER -